Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07610473 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
A Phase 2 study, sponsored by Draig Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT07610473 is a Phase 2 study that is actively recruiting participants, run by Draig Therapeutics. The registered enrollment target is 118 participants.
The verdict
NCT07610473, a Phase 2 study, is actively recruiting participants, sponsored by Draig Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo looks the drug but contains no medicine. Subjects will attend the clinic for complete general health checks and to complete questionnaires.
Interventions
- DRUG Placebo
- DRUG DT-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2026-05 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07610473
The ClinicalTrials.gov registry entry for NCT07610473 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Draig Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07610473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07610473 about?
NCT07610473 is a clinical study titled "A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression". In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo lo...
What is the current status of trial NCT07610473?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2026-05. Estimated completion is 2027-05.
What interventions are being tested in trial NCT07610473?
The interventions under investigation include: Placebo (DRUG), DT-101 (DRUG).
Who is sponsoring clinical trial NCT07610473?
This trial is sponsored by Draig Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.